Celldex Therapeutics, Inc.

CLDX

US15117B2025

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 15:29:06 2024-05-28 EDT			5-day change	1st Jan Change
35.34 ^USD	-4.29%		-6.64%	-11.32%

05-15	Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study	MT
05-15	Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis	CI

Celldex Therapeutics, Inc. Announces the Resignation of Thomas Davis as Executive Vice President and Chief Medical Officer, Effective September 29, 2017

September 12, 2017 at 04:01 pm

Celldex Therapeutics, Inc. announced the resignation of Thomas Davis, M.D., as Executive Vice President and Chief Medical Officer of the company, effective September 29, 2017.

Latest news about Celldex Therapeutics, Inc.

Celldex Therapeutics Reports First Patient Dosed in Phase 2 Skin Disorder Study	05-15	MT
Celldex Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Prurigo Nodularis	05-15	CI
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q1 Revenue $156,000	05-06	MT
Celldex Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-06	CI
Sector Update: Health Care Stocks Mixed Wednesday Afternoon	04-17	MT
Celldex Therapeutics Says Patient Enrollment Completed in Chronic Inducible Urticaria Treatment Study; Shares Rise	04-17	MT
Celldex Therapeutics, Inc. Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria	04-17	CI
Celldex Therapeutics Prices $400.4 Million Common Stock Offering	03-01	MT
Celldex Therapeutics Proposes $250 Million Underwritten Common Stock Offering	02-28	MT
Sector Update: Health Care Stocks Weaker Monday Afternoon	02-26	MT
Celldex Therapeutics Shares Rise After Q4 Revenue Tops Estimates	02-26	MT
Sector Update: Health Care Stocks Mixed Premarket Monday	02-26	MT
Celldex Therapeutics Q4 Loss Widens, Revenue Rises; Shares Up Pre-Bell	02-26	MT
Earnings Flash (CLDX) CELLDEX THERAPEUTICS Posts Q4 Revenue $4.1M	02-26	MT
Celldex Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-26	CI
Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-26	CI
Transcript : Celldex Therapeutics, Inc. - Special Call	02-25
TD Cowen Initiates Celldex Therapeutics at Outperform Rating	12-20	MT
North American Morning Briefing : Stock Futures -2-	11-13	DJ
Wells Fargo Upgrades Celldex Therapeutics to Equalweight From Underweight With $27 Price Target	11-10	MT
Celldex Therapeutics Prices $200.5 Million Share Offering	11-08	MT
Celldex Shares Rise as Phase 2 Trial Shows Barzolvolimab Meets Primary Efficacy Endpoint for Chronic Spontaneous Urticaria	11-06	MT
HC Wainwright Adjusts Price Target on Celldex Therapeutics to $80 From $73, Maintains Buy Rating	11-06	MT
Sector Update: Health Care Stocks Advance Premarket Monday	11-06	MT
Traders Await Next Catalyst as US Equity Futures Edge Higher Pre-Bell	11-06	MT

Chart Celldex Therapeutics, Inc.

Duration

Period

More charts

Celldex Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases for which available treatments are inadequate. Its Barzolvolimab, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis and Eosinophilic Esophagitis. The Companyâs bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology. Bispecific Platform includes CDX-585. CDX-585 combines its highly active PD-1 blockade and anti-ILT4 blockade to overcome immunosuppressive signals in T cells and myeloid cells, respectively.

Sector

Biotechnology & Medical Research

Calendar

2024-06-12 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Celldex Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

36.92 USD

Average target price

69 USD

Spread / Average Target

+86.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CELLDEX THERAPEUTICS, INC.	-11.32%	2.43B
MODERNA, INC.	+52.38%	63.85B
IQVIA HOLDINGS INC.	-2.44%	41.83B
LONZA GROUP AG	+40.01%	40.47B
CELLTRION, INC.	-10.22%	27.17B
ICON PUBLIC LIMITED COMPANY	+13.09%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-21.58%	18.69B
BIO-TECHNE CORPORATION	+2.80%	12.73B
UNITED THERAPEUTICS CORPORATION	+22.41%	12.11B
MEDPACE HOLDINGS, INC.	+27.56%	12.07B

Other Biotechnology & Medical Research